CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours door J. Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y. Chung, Judy Wang, Gerald Falchook, James M. Cleary, Richard Kim, Anuradha Krishnamurthy, Omkar Marathe, Hagop Youssoufian, Catherine Ellis, Angela Waszak, Srimoyee Ghosh, Hailei Zhang, Kaitlin Yablonski, Shruti D. Shah, Ivan Diaz-Padilla, Susanna Ulahannan

Volledige tekst